Linda Palczuk - Jan 20, 2023 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Role
Director
Signature
/s/ Jerad G. Seurer, as attorney-in-fact
Stock symbol
AVDL
Transactions as of
Jan 20, 2023
Transactions value $
$0
Form type
4
Date filed
1/24/2023, 04:00 PM
Previous filing
Dec 28, 2022
Next filing
May 10, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVDL Stock Option (Right to Buy) Gift $0 -60K -100% $0.00* 0 Jan 20, 2023 ADSs 60K $2.03 Direct F1, F2
transaction AVDL Stock Option (Right to Buy) Gift $0 -42K -100% $0.00* 0 Jan 20, 2023 ADSs 42K $8.48 Direct F2, F4
transaction AVDL Stock Option (Right to Buy) Gift $0 -42K -100% $0.00* 0 Jan 20, 2023 ADSs 42K $8.07 Direct F1, F2
transaction AVDL Stock Option (Right to Buy) Gift $0 -42K -100% $0.00* 0 Jan 20, 2023 ADSs 42K $4.79 Direct F2, F5
holding AVDL Stock Option (Right to Buy) 60K Jan 20, 2023 ADSs 60K $2.03 By Trust F1, F2, F3
holding AVDL Stock Option (Right to Buy) 42K Jan 20, 2023 ADSs 42K $8.48 By Trust F2, F3, F4
holding AVDL Stock Option (Right to Buy) 42K Jan 20, 2023 ADSs 42K $8.07 By Trust F1, F2, F3
holding AVDL Stock Option (Right to Buy) 42K Jan 20, 2023 ADSs 42K $4.79 By Trust F2, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options are fully vested and exercisable as of the date hereof.
F2 The Issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
F3 On January 20, 2023, the Reporting Person transferred an aggregate of 186,000 options to a revocable trust of which the Reporting Person is trustee.
F4 These options become exercisable as to 14,000 ADSs on each of the first three anniversaries after the 08/07/2020 grant date, subject to the Reporting Person's continued service at each such vesting date.
F5 These options shall vest in full on the earlier to occur of (a) August 3, 2023 or (b) the date of the next annual general meeting of shareholders following the date of grant, subject to the Reporting Person's continued service on the Board of Directors at such time.